Precision Performance

As a pharmaceutical research & development company, we identify compelling emergent drugs and drive them through the evaluation and clinical trial processes to a successful market launch.

For example, a new drug candidate to treat the most aggressive form of breast cancer—triple negative breast cancer—is halfway through the Investigational New Drug (IND) process required by the FDA. Independent research now confirms significant tumor reduction with no toxicity. This drug exceeds the gold standard in drug development, “Lipinski’s Rule of 5,” which enhances the probability of reaching the market. Approximately 90% of all adult cancers are solid tumors. USPM is seeking big pharma partners to complete the next stage clinical research.